| Insideraktier | 4 186 375 shares |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Nettoantalet insiders som köper (rankning)
N/A
Nettoantalet insiders som köper är den totala mängden insiders som säljer minus det totala antalet insiders som säljer under de senaste 90 dagarna. Percentilrankningen visas här (intervall från 0 till 100%).
Procent av flytande köpta av insiders (ranking)
N/A
Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
GlycoMimetics, Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i GLYC / GlycoMimetics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i GLYC / GlycoMimetics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-23 | 3 | Doughty Christopher Grant | CBIO | Ordinary Shares | D | 39 480 | ||||||||
| 2025-06-23 | 3 | Brumm Joshua T | CBIO | Ordinary Shares | D | 268 400 | ||||||||
| 2025-06-23 | 3 | McNeill Jonathan | CBIO | Ordinary Shares | D | 134 200 | ||||||||
| 2025-06-23 | 3 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. | CBIO | Ordinary Shares | I | 1 387 866 | ||||||||
| 2025-06-23 | 3 | Violin Jonathan | CBIO | Ordinary Shares | D | 69 515 | ||||||||
| 2025-06-17 | 2025-06-13 | 4 | BVF PARTNERS L P/IL | CBIO | Common Stock | D | 56 079 | 62 383 | ||||||
| 2025-06-17 | 2025-06-13 | 4 | BVF PARTNERS L P/IL | CBIO | Common Stock | D | 556 617 | 593 740 | ||||||
| 2025-06-17 | 2025-06-13 | 4 | BVF PARTNERS L P/IL | CBIO | Common Stock | D | 657 308 | 707 116 | ||||||
| 2024-08-09 | 2024-08-08 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,1917 | −260 873 | −50 | 6 317 565 | ||||
| 2024-08-09 | 2024-08-07 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,1821 | −61 488 | −11 | 6 578 438 | ||||
| 2024-08-07 | 2024-08-06 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,1828 | −55 732 | −10 | 6 639 926 | ||||
| 2024-08-07 | 2024-08-05 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,1884 | −164 523 | −31 | 6 695 658 | ||||
| 2024-08-05 | 2024-08-02 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,2004 | −286 200 | −57 | 6 860 181 | ||||
| 2024-08-05 | 2024-08-01 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,2162 | −63 564 | −14 | 7 146 381 | ||||
| 2024-07-30 | 2024-07-30 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,2209 | −756 835 | −167 | 7 209 945 | ||||
| 2024-07-30 | 2024-07-29 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,2353 | −363 949 | −86 | 7 966 780 | ||||
| 2024-07-30 | 2024-07-26 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 0,2417 | −258 335 | −62 | 8 330 729 | ||||
| 2024-07-29 | 3 | Siren, L.L.C. | GLYC | Common Stock | D | 8 589 064 | ||||||||
| 2024-06-24 | 2024-06-21 | 4 | Rock Edwin | GLYC | Common Stock | D | 0,2671 | 115 000 | 31 | 680 403 | ||||
| 2024-06-24 | 2024-06-20 | 4 | Rock Edwin | GLYC | Common Stock | D | 0,2532 | 190 000 | 48 | 565 403 | ||||
| 2024-06-20 | 2024-06-18 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 0,2477 | 17 500 | 4 | 70 643 | ||||
| 2024-04-02 | 2024-03-29 | 4 | Goldberg Mark Alan | GLYC | Common Stock | D | 3,0000 | 4 584 | 14 | 24 828 | ||||
| 2024-04-02 | 2024-03-29 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 3,0000 | 5 209 | 16 | 98 459 | ||||
| 2024-04-02 | 2024-03-29 | 4 | King Rachel K. | GLYC | Common Stock | D | 3,0000 | 3 334 | 10 | 515 194 | ||||
| 2024-01-02 | 2023-12-29 | 4 | Goldberg Mark Alan | GLYC | Common stock | D | 2,3600 | 5 827 | 14 | 20 244 | ||||
| 2024-01-02 | 2023-12-29 | 4 | King Rachel K. | GLYC | Common stock | D | 2,3600 | 4 238 | 10 | 511 860 | ||||
| 2024-01-02 | 2023-12-29 | 4 | Andrews Patricia S | GLYC | Common stock | D | 2,3600 | 5 191 | 12 | 58 608 | ||||
| 2023-10-03 | 2023-09-30 | 4 | Goldberg Mark Alan | GLYC | Common stock | D | 1,5000 | 9 167 | 14 | 14 417 | ||||
| 2023-10-03 | 2023-09-30 | 4 | King Rachel K. | GLYC | Common stock | D | 1,5000 | 6 667 | 10 | 507 622 | ||||
| 2023-10-03 | 2023-09-30 | 4 | Andrews Patricia S | GLYC | Common stock | D | 1,5000 | 8 167 | 12 | 53 417 | ||||
| 2023-09-25 | 2023-09-22 | 4 | Rock Edwin | GLYC | Common Stock | D | 1,3800 | 30 403 | 42 | 375 403 | ||||
| 2023-09-25 | 2023-09-21 | 4 | Rock Edwin | GLYC | Common Stock | D | 1,3800 | 35 000 | 48 | 345 000 | ||||
| 2023-06-02 | 2023-06-01 | 4 | Koenig Scott | GLYC | Common Stock | D | 0,6000 | 21 000 | 13 | 36 750 | ||||
| 2023-05-18 | 2023-05-17 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,9500 | −3 700 | −7 | 53 143 | ||||
| 2023-05-11 | 2023-05-10 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 1,5600 | 30 000 | 47 | 93 250 | ||||
| 2023-05-09 | 2023-05-08 | 4 | Johnson Bruce S | GLYC | Common Stock | D | 1,5700 | 13 500 | 21 | 138 980 | ||||
| 2023-03-31 | 3 | Rath Chinmaya | GLYC | Common Stock | D | 161 178 | ||||||||
| 2023-03-31 | 3 | Johnson Bruce S | GLYC | Common Stock | D | 125 480 | ||||||||
| 2023-02-28 | 2023-02-24 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,7000 | 100 000 | 170 | 8 589 064 | ||||
| 2023-02-23 | 2023-02-23 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,7538 | 200 000 | 351 | 8 489 064 | ||||
| 2023-02-23 | 2023-02-22 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,7933 | 150 000 | 269 | 8 289 064 | ||||
| 2023-02-23 | 2023-02-21 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,8500 | 50 000 | 92 | 8 139 064 | ||||
| 2023-02-17 | 2023-02-17 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,7050 | 200 000 | 341 | 8 089 064 | ||||
| 2023-02-17 | 2023-02-16 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 1,6847 | 315 266 | 531 | 7 889 064 | ||||
| 2023-02-17 | 2023-02-15 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 2,1558 | 1 000 000 | 2 156 | 7 573 798 | ||||
| 2023-02-13 | 2023-02-09 | 4 | Invus Public Equities, L.P. | GLYC | Common Stock | D | 3,2419 | 11 451 | 37 | 6 573 798 | ||||
| 2023-02-13 | 3 | Invus Public Equities Advisors, LLC | GLYC | Common Stock | D | 6 562 347 | ||||||||
| 2023-02-06 | 2022-08-02 | 5 | King Rachel K. By RBK LLC | GLYC | Common Stock | I | 7 500 | 7 500 | ||||||
| 2023-02-06 | 2022-02-15 | 5 | King Rachel K. | GLYC | Common Stock | D | 11 641 | 500 955 | ||||||
| 2023-01-30 | 2023-01-27 | 4 | Koenig Scott | GLYC | Common Stock | D | 2,5500 | 10 500 | 27 | 15 750 | ||||
| 2023-01-27 | 2023-01-26 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 3,1188 | −1 351 092 | −4 214 | 2 237 196 | ||||
| 2023-01-27 | 2023-01-26 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 3,1188 | −1 648 908 | −5 143 | 2 730 334 | ||||
| 2023-01-27 | 2023-01-25 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 3,2639 | −293 645 | −958 | 3 588 288 | ||||
| 2023-01-27 | 2023-01-25 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 3,2639 | −358 371 | −1 170 | 4 379 242 | ||||
| 2023-01-06 | 2023-01-05 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 2,7586 | −32 139 | −89 | 3 881 933 | ||||
| 2023-01-06 | 2023-01-05 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 2,7586 | −39 223 | −108 | 4 737 613 | ||||
| 2023-01-04 | 2023-01-04 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 2,9097 | −45 930 | −134 | 3 914 072 | ||||
| 2023-01-04 | 2023-01-04 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 2,9097 | −56 054 | −163 | 4 776 836 | ||||
| 2023-01-04 | 2023-01-03 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 2,9901 | −78 730 | −235 | 3 960 002 | ||||
| 2023-01-04 | 2023-01-03 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 2,9901 | −96 084 | −287 | 4 832 890 | ||||
| 2023-01-04 | 2022-12-30 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 3,0200 | −54 645 | −165 | 4 038 732 | ||||
| 2023-01-04 | 2022-12-30 | 4 | SANDELL SCOTT D See Note 2 | GLYC | Common Stock | I | 3,0200 | −66 690 | −201 | 4 928 974 | ||||
| 2022-12-27 | 2022-12-22 | 4 | Rock Edwin | GLYC | Common Stock | D | 2,2500 | 110 000 | 248 | 310 000 | ||||
| 2022-11-18 | 2022-11-17 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 1,8700 | 20 000 | 37 | 63 250 | ||||
| 2022-11-16 | 2022-11-15 | 4 | Rock Edwin | GLYC | Common Stock | D | 1,6600 | 100 000 | 166 | 200 000 | ||||
| 2022-11-16 | 2022-11-14 | 4 | Rock Edwin | GLYC | Common Stock | D | 1,4300 | 100 000 | 143 | 100 000 | ||||
| 2022-11-14 | 2022-11-11 | 4 | Magnani John L. | GLYC | Common Stock | D | 1,1700 | 45 045 | 53 | 366 078 | ||||
| 2022-11-14 | 2022-11-11 | 4 | PEARSON TIMOTHY R | GLYC | Common Stock | D | 1,2900 | 19 400 | 25 | 24 650 | ||||
| 2022-11-14 | 2022-11-11 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,0600 | 20 000 | 21 | 56 843 | ||||
| 2022-11-14 | 2022-11-11 | 4 | Semerjian Harout | GLYC | Common Stock | D | 1,2900 | 25 000 | 32 | 25 000 | ||||
| 2022-11-14 | 2022-11-11 | 4 | Girard Armand | GLYC | Common Stock | D | 1,0500 | 6 500 | 7 | 29 161 | ||||
| 2022-09-07 | 3 | Rock Edwin | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2022-05-20 | 2022-05-18 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | King Rachel K. | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | Jackson Scott Thomas | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-05-20 | 2022-05-18 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 0,60 | 21 000 | 21 000 | |||||
| 2022-03-10 | 2022-03-09 | 4 | Magnani John L. | GLYC | Common Stock | D | 1,0900 | −3 227 | −4 | 321 033 | ||||
| 2022-03-10 | 2022-03-09 | 4 | Girard Armand | GLYC | Common Stock | D | 1,0900 | −2 339 | −3 | 22 661 | ||||
| 2022-03-10 | 2022-03-09 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,0900 | −2 917 | −3 | 36 843 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Girard Armand | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 47 700 | 47 700 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Girard Armand | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 144 700 | 144 700 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 25 000 | 25 000 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 100 000 | 100 000 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 47 700 | 47 700 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 164 700 | 164 700 | |||||
| 2022-01-25 | 2022-01-21 | 4 | Semerjian Harout | GLYC | Employee Stock Option (right to buy) | D | 1,11 | 423 500 | 423 500 | |||||
| 2021-11-18 | 2021-11-16 | 4 | Andrews Patricia S | GLYC | Common Stock | D | 2,0500 | 40 000 | 82 | 45 250 | ||||
| 2021-08-10 | 3 | Semerjian Harout | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2021-05-27 | 2021-05-18 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 5 250 | 43 250 | ||||||
| 2021-05-27 | 2021-05-18 | 4 | Jackson Scott Thomas | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | Jackson Scott Thomas | GLYC | Common Stock | D | 5 250 | 5 250 | ||||||
| 2021-05-27 | 2021-05-18 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | Andrews Patricia S | GLYC | Common Stock | D | 5 250 | 5 250 | ||||||
| 2021-05-27 | 2021-05-18 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | Goldberg Mark Alan | GLYC | Common Stock | D | 5 250 | 5 250 | ||||||
| 2021-05-27 | 2021-05-18 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | Koenig Scott | GLYC | Common Stock | D | 5 250 | 5 250 | ||||||
| 2021-05-27 | 2021-05-18 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 2,55 | 10 500 | 10 500 | |||||
| 2021-05-27 | 2021-05-18 | 4 | PEARSON TIMOTHY R | GLYC | Common Stock | D | 5 250 | 5 250 | ||||||
| 2021-03-08 | 3 | Feldman Eric Jay | GLYC | Common Stock | D | 50 498 | ||||||||
| 2021-01-22 | 2021-01-20 | 4 | Girard Armand | GLYC | Employee Stock Option (right to buy) | D | 3,81 | 50 000 | 50 000 | |||||
| 2021-01-22 | 2021-01-20 | 4 | Girard Armand | GLYC | Common Stock | D | 25 000 | 25 000 | ||||||
| 2021-01-22 | 2021-01-20 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 3,81 | 69 000 | 69 000 | |||||
| 2021-01-22 | 2021-01-20 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 34 500 | 39 760 | ||||||
| 2021-01-22 | 2021-01-20 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 3,81 | 69 000 | 69 000 | |||||
| 2021-01-22 | 2021-01-20 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 34 500 | 183 115 | ||||||
| 2021-01-22 | 2021-01-20 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 3,81 | 69 000 | 69 000 | |||||
| 2021-01-22 | 2021-01-20 | 4 | Magnani John L. | GLYC | Common Stock | D | 34 500 | 324 260 | ||||||
| 2021-01-22 | 2021-01-20 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 3,81 | 192 500 | 192 500 | |||||
| 2021-01-22 | 2021-01-20 | 4 | King Rachel K. | GLYC | Common Stock | D | 96 250 | 452 314 | ||||||
| 2020-12-30 | 2020-12-28 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −130 821 | 0 | |||||
| 2020-12-30 | 2020-12-28 | 4 | King Rachel K. | GLYC | Common Stock | D | 3,9100 | −84 176 | −329 | 356 064 | ||||
| 2020-12-30 | 2020-12-28 | 4 | King Rachel K. | GLYC | Common Stock | D | 1,1200 | 130 821 | 147 | 440 240 | ||||
| 2020-12-17 | 2020-12-16 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −5 260 | 0 | |||||
| 2020-12-17 | 2020-12-16 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,1200 | 5 260 | 6 | 5 260 | ||||
| 2020-11-06 | 2020-11-04 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,6000 | 86 090 | 224 | 630 453 | ||||
| 2020-11-06 | 2020-11-04 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,6000 | 506 155 | 1 316 | 3 712 350 | ||||
| 2020-11-06 | 2020-11-04 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,6000 | 674 492 | 1 754 | 4 980 812 | ||||
| 2020-11-03 | 2020-10-30 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,7500 | 15 472 | 43 | 544 363 | ||||
| 2020-11-03 | 2020-10-30 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,7500 | 250 755 | 690 | 3 206 195 | ||||
| 2020-11-03 | 2020-10-30 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 2,7500 | 666 385 | 1 833 | 4 306 320 | ||||
| 2020-05-27 | 2020-05-22 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-05-27 | 2020-05-22 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-05-27 | 2020-05-22 | 4 | Jackson Scott Thomas | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-05-27 | 2020-05-22 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-05-27 | 2020-05-22 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-05-27 | 2020-05-22 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 3,00 | 21 000 | 21 000 | |||||
| 2020-03-10 | 2020-03-09 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 3,4000 | 20 000 | 68 | 38 000 | ||||
| 2020-01-24 | 2020-01-22 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 4,72 | 349 000 | 349 000 | |||||
| 2020-01-24 | 2020-01-22 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 4,72 | 120 000 | 120 000 | |||||
| 2020-01-24 | 2020-01-22 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 4,72 | 120 000 | 120 000 | |||||
| 2020-01-24 | 2020-01-22 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 4,72 | 120 000 | 120 000 | |||||
| 2020-01-24 | 2020-01-22 | 4 | Girard Armand | GLYC | Employee Stock Option (right to buy) | D | 4,72 | 100 000 | 100 000 | |||||
| 2020-01-06 | 2020-01-06 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −106 983 | 0 | |||||
| 2020-01-06 | 2020-01-06 | 4 | Magnani John L. | GLYC | Common Stock | D | 1,1200 | 106 983 | 120 | 289 760 | ||||
| 2019-12-23 | 2019-12-20 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −106 984 | 106 983 | |||||
| 2019-12-23 | 2019-12-20 | 4 | Magnani John L. | GLYC | Common Stock | D | 1,1200 | 106 984 | 120 | 182 777 | ||||
| 2019-09-09 | 2019-09-05 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 3,1820 | 124 956 | 398 | 528 891 | ||||
| 2019-09-09 | 2019-09-05 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 3,1820 | 689 834 | 2 195 | 2 955 440 | ||||
| 2019-09-09 | 2019-09-05 | 4 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value | D | 3,1820 | 853 956 | 2 717 | 3 639 935 | ||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 7 721 126 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 5 859 455 | ||||||||
| 2019-08-26 | 3 | LAMPERT MARK N | GLYC | Common Stock, $0.001 par value | D | 8 241 499 | ||||||||
| 2019-08-15 | 2019-08-13 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 3,1800 | 10 000 | 32 | 18 000 | ||||
| 2019-08-07 | 2019-08-06 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −166 759 | 130 821 | |||||
| 2019-08-07 | 2019-08-06 | 4 | King Rachel K. | GLYC | Common Stock | D | 1,1200 | 166 759 | 187 | 307 144 | ||||
| 2019-05-21 | 2019-05-17 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-05-21 | 2019-05-17 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-05-21 | 2019-05-17 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-05-21 | 2019-05-17 | 4 | Jackson Scott Thomas | GLYC | Stock Option (right to buy) | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-05-21 | 2019-05-17 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-05-21 | 2019-05-17 | 4 | PEARSON TIMOTHY R | GLYC | Common Stock | D | 12,39 | 21 000 | 21 000 | |||||
| 2019-01-22 | 2019-01-17 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 10,59 | 90 000 | 90 000 | |||||
| 2019-01-22 | 2019-01-17 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 10,59 | 100 000 | 100 000 | |||||
| 2019-01-22 | 2019-01-17 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 10,59 | 100 000 | 100 000 | |||||
| 2019-01-22 | 2019-01-17 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 10,59 | 265 000 | 265 000 | |||||
| 2018-11-28 | 3 | Jackson Scott Thomas | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2018-11-28 | 2018-11-27 | 4 | Jackson Scott Thomas | GLYC | Stock Option (right to buy) | D | 11,52 | 22 000 | 22 000 | |||||
| 2018-10-18 | 2018-10-18 | 4 | Magnani John L. | GLYC | Common Stock | D | 14,0200 | −3 527 | −49 | 75 793 | ||||
| 2018-10-18 | 2018-10-17 | 4 | Magnani John L. | GLYC | Common Stock | D | 14,0000 | −7 273 | −102 | 79 320 | ||||
| 2018-10-18 | 2018-10-16 | 4 | Magnani John L. | GLYC | Common Stock | D | 14,0100 | −14 200 | −199 | 86 593 | ||||
| 2018-06-12 | 2018-06-11 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −5 260 | 5 260 | |||||
| 2018-06-12 | 2018-06-11 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 18,0400 | −19 345 | −349 | 0 | ||||
| 2018-06-12 | 2018-06-11 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,1200 | 5 260 | 6 | 19 345 | ||||
| 2018-05-24 | 2018-05-23 | 4 | Magnani John L. | GLYC | Warrant to Purchase Common Stock (right to buy) | D | 0,33 | −596 | 0 | |||||
| 2018-05-24 | 2018-05-23 | 4 | Magnani John L. | GLYC | Warrant to Purchase Common Stock (right to buy) | D | 0,33 | −895 | 0 | |||||
| 2018-05-24 | 2018-05-23 | 4 | Magnani John L. | GLYC | Common Stock | D | 0,3300 | 1 491 | 0 | 100 793 | ||||
| 2018-05-21 | 2018-05-18 | 4 | BARRETT M JAMES | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-21 | 2018-05-18 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-21 | 2018-05-18 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-21 | 2018-05-18 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-21 | 2018-05-18 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-21 | 2018-05-18 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 18,41 | 11 000 | 11 000 | |||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Warrant to Purchase Common Stock (right to buy) | D | 0,33 | −298 406 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Warrant to Purchase Common Stock (right to buy) | D | 0,33 | −216 046 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 17,8100 | −5 533 | −99 | 4 995 664 | ||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 0,3300 | 298 406 | 98 | 5 001 197 | ||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 17,8100 | −4 006 | −71 | 4 702 791 | ||||
| 2018-05-11 | 2018-05-10 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 0,3300 | 216 046 | 71 | 4 706 797 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −298 406 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −216 046 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 17,8100 | −5 533 | −99 | 4 995 664 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 0,3300 | 298 406 | 98 | 5 001 197 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 17,8100 | −4 006 | −71 | 4 702 791 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 0,3300 | 216 046 | 71 | 4 706 797 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −298 406 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −216 046 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 17,8100 | −5 533 | −99 | 4 995 664 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 0,3300 | 298 406 | 98 | 5 001 197 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 17,8100 | −4 006 | −71 | 4 702 791 | ||||
| 2018-05-11 | 2018-05-10 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 0,3300 | 216 046 | 71 | 4 706 797 | ||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −298 406 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −216 046 | 0 | |||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 17,8100 | −5 533 | −99 | 4 995 664 | ||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 0,3300 | 298 406 | 98 | 5 001 197 | ||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 17,8100 | −4 006 | −71 | 4 702 791 | ||||
| 2018-05-11 | 2018-05-10 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 0,3300 | 216 046 | 71 | 4 706 797 | ||||
| 2018-02-14 | 2017-09-08 | 5 | King Rachel K. By The Rachel K. King 2013 GRAT | GLYC | Common Stock | I | −46 602 | 0 | ||||||
| 2018-02-14 | 2017-09-08 | 5 | King Rachel K. By Langley King 2013 GRAT | GLYC | Common Stock | I | 23 301 | 23 301 | ||||||
| 2018-02-14 | 2017-09-08 | 5 | King Rachel K. By Connor King 2013 GRAT | GLYC | Common Stock | I | 23 301 | 23 301 | ||||||
| 2018-01-12 | 2018-01-10 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 20,03 | 65 000 | 65 000 | |||||
| 2018-01-12 | 2018-01-10 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 20,03 | 75 000 | 75 000 | |||||
| 2018-01-12 | 2018-01-10 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 20,03 | 75 000 | 75 000 | |||||
| 2018-01-12 | 2018-01-10 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 20,03 | 175 000 | 175 000 | |||||
| 2017-12-12 | 2017-12-08 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 15,0100 | −2 000 | −30 | 148 615 | ||||
| 2017-09-18 | 2017-09-18 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 13,0000 | −2 000 | −26 | 150 615 | ||||
| 2017-06-16 | 2017-06-15 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 11,2700 | 3 000 | 34 | 8 000 | ||||
| 2017-06-12 | 3 | Andrews Patricia S | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2017-06-12 | 2017-06-09 | 4 | Andrews Patricia S | GLYC | Stock Option (right to buy) | D | 11,63 | 22 000 | 22 000 | |||||
| 2017-05-30 | 2017-05-25 | 4 | BARRETT M JAMES | GLYC | Stock Option (right to buy) | D | 13,89 | 11 000 | 11 000 | |||||
| 2017-05-30 | 2017-05-25 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 15,5700 | −2 000 | −31 | 152 615 | ||||
| 2017-05-30 | 2017-05-25 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 13,89 | 11 000 | 11 000 | |||||
| 2017-05-30 | 2017-05-25 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 13,89 | 11 000 | 11 000 | |||||
| 2017-05-30 | 2017-05-25 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 13,89 | 11 000 | 11 000 | |||||
| 2017-05-30 | 2017-05-25 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 13,89 | 11 000 | 11 000 | |||||
| 2017-05-22 | 2017-05-19 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 12,1400 | −2 000 | −24 | 154 615 | ||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 665 288 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 4 098 367 | ||||||||
| 2017-05-11 | 3 | BVF PARTNERS L P/IL | GLYC | Common Stock, $0.001 par value per share | D | 3 319 001 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −8 928 | 213 967 | |||||
| 2017-05-11 | 2017-05-10 | 4 | Magnani John L. | GLYC | Common Stock | D | 1,1200 | 8 928 | 10 | 99 302 | ||||
| 2017-03-13 | 3 | Koenig Scott | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2017-03-13 | 2017-03-09 | 4 | Koenig Scott | GLYC | Stock Option (right to buy) | D | 6,59 | 22 000 | 22 000 | |||||
| 2017-01-05 | 2017-01-04 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 6,33 | 65 000 | 65 000 | |||||
| 2017-01-05 | 2017-01-04 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 6,33 | 175 000 | 175 000 | |||||
| 2017-01-05 | 2017-01-04 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 6,33 | 75 000 | 75 000 | |||||
| 2017-01-05 | 2017-01-04 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 6,33 | 75 000 | 75 000 | |||||
| 2016-12-21 | 2016-12-20 | 4 | JUNIUS DANIEL M | GLYC | Common Stock | D | 6,0100 | 5 000 | 30 | 5 000 | ||||
| 2016-10-04 | 2016-10-03 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 7,0100 | −100 | −1 | 156 615 | ||||
| 2016-10-04 | 2016-10-03 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 7,0000 | −3 900 | −27 | 156 715 | ||||
| 2016-07-21 | 2016-07-20 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 8,0000 | −2 000 | −16 | 160 615 | ||||
| 2016-07-06 | 2016-07-06 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 6,6800 | −6 796 | −45 | 162 615 | ||||
| 2016-07-06 | 2016-07-05 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 7,0100 | −10 136 | −71 | 169 411 | ||||
| 2016-07-06 | 2016-07-01 | 4 | Thackray Helen M. | GLYC | Common Stock | D | 7,4000 | −5 068 | −38 | 179 547 | ||||
| 2016-07-01 | 2016-06-29 | 4 | Baldwin John J. | GLYC | Stock Option (right to buy) | D | 1,12 | −605 | 0 | |||||
| 2016-07-01 | 2016-06-29 | 4 | Baldwin John J. | GLYC | Common Stock | D | 1,1200 | 605 | 1 | 1 210 | ||||
| 2016-05-19 | 2016-05-17 | 4/A | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | TOP FRANKLIN H JR | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | BARRETT M JAMES | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Baldwin John J. | GLYC | Stock Option (right to buy) | D | 6,35 | 11 000 | 11 000 | |||||
| 2016-03-21 | 3 | JUNIUS DANIEL M | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2016-03-21 | 2016-03-17 | 4 | JUNIUS DANIEL M | GLYC | Stock Option (right to buy) | D | 5,99 | 22 000 | 22 000 | |||||
| 2016-03-07 | 2016-03-04 | 4 | Goldberg Mark Alan | GLYC | Common Stock | D | 4,7735 | 10 397 | 50 | 11 497 | ||||
| 2016-02-12 | 2016-02-05 | 4 | TOP FRANKLIN H JR | GLYC | Stock Option (right to buy) | D | 1,12 | 1,1200 | −11 084 | −12 | 0 | |||
| 2016-02-12 | 2016-02-05 | 4 | TOP FRANKLIN H JR | GLYC | Stock Option (right to buy) | D | 1,12 | 1,1200 | −605 | −1 | 0 | |||
| 2016-02-12 | 2016-02-05 | 4 | TOP FRANKLIN H JR | GLYC | Common Stock | D | 1,1200 | 11 689 | 13 | 12 294 | ||||
| 2016-01-11 | 2016-01-07 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 5,22 | 65 000 | 65 000 | |||||
| 2016-01-11 | 2016-01-07 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 5,22 | 141 000 | 141 000 | |||||
| 2016-01-11 | 2016-01-07 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 5,22 | 71 000 | 71 000 | |||||
| 2016-01-11 | 2016-01-07 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 5,22 | 71 000 | 71 000 | |||||
| 2015-11-18 | 2015-11-16 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | 0,3300 | −9 445 | −3 | 0 | |||
| 2015-11-18 | 2015-11-16 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 6,9100 | −452 | −3 | 4 490 751 | ||||
| 2015-11-18 | 2015-11-16 | 4 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 0,3300 | 9 445 | 3 | 4 491 203 | ||||
| 2015-11-18 | 2015-11-16 | 4 | BARRETT M JAMES See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | 0,3300 | −9 445 | −3 | 0 | |||
| 2015-11-18 | 2015-11-16 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 6,9100 | −452 | −3 | 4 490 751 | ||||
| 2015-11-18 | 2015-11-16 | 4 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 0,3300 | 9 445 | 3 | 4 491 203 | ||||
| 2015-11-18 | 2015-11-16 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Warrant to Purchase Common Stock (right to buy) | D | 0,33 | 0,3300 | −9 445 | −3 | 0 | |||
| 2015-11-18 | 2015-11-16 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 6,9100 | −452 | −3 | 4 490 751 | ||||
| 2015-11-18 | 2015-11-16 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 0,3300 | 9 445 | 3 | 4 491 203 | ||||
| 2015-11-18 | 2015-11-16 | 4 | BARRIS PETER J See Note 1 | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | 0,3300 | −9 445 | −3 | 0 | |||
| 2015-11-18 | 2015-11-16 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 6,9100 | −452 | −3 | 4 490 751 | ||||
| 2015-11-18 | 2015-11-16 | 4 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 0,3300 | 9 445 | 3 | 4 491 203 | ||||
| 2015-08-11 | 2015-07-15 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-08-11 | 2015-07-15 | 4 | Baldwin John J. | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-08-11 | 2015-07-15 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-08-11 | 2015-07-15 | 4 | HENOS MICHAEL A | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-08-11 | 2015-07-15 | 4 | TOP FRANKLIN H JR | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-08-11 | 2015-07-15 | 4 | BARRETT M JAMES | GLYC | Stock Option (right to buy) | D | 7,50 | 11 000 | 11 000 | |||||
| 2015-03-03 | 2015-02-27 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −5 000 | 10 520 | |||||
| 2015-03-03 | 2015-02-27 | 4 | Hahn Brian M. | GLYC | Common Stock | D | 1,1200 | 5 000 | 6 | 14 085 | ||||
| 2015-02-26 | 2015-02-24 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −50 000 | 297 580 | |||||
| 2015-02-26 | 2015-02-24 | 4 | King Rachel K. | GLYC | Common Stock | D | 1,1200 | 50 000 | 56 | 167 206 | ||||
| 2015-01-12 | 2015-01-08 | 4 | Thackray Helen M. | GLYC | Employee Stock Option (right to buy) | D | 7,15 | 71 000 | 71 000 | |||||
| 2015-01-12 | 2015-01-08 | 4 | Hahn Brian M. | GLYC | Employee Stock Option (right to buy) | D | 7,15 | 61 000 | 61 000 | |||||
| 2015-01-12 | 2015-01-08 | 4 | Magnani John L. | GLYC | Employee Stock Option (right to buy) | D | 7,15 | 71 000 | 71 000 | |||||
| 2015-01-12 | 2015-01-08 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 7,15 | 141 000 | 141 000 | |||||
| 2014-12-23 | 2014-12-22 | 4 | HENOS MICHAEL A By fund | GLYC | Common Stock | I | 8,4354 | −10 659 | −90 | 469 454 | ||||
| 2014-12-23 | 2014-12-19 | 4 | HENOS MICHAEL A By fund | GLYC | Common Stock | I | 8,6127 | −10 598 | −91 | 480 113 | ||||
| 2014-12-17 | 2014-12-17 | 4 | HENOS MICHAEL A By funds | GLYC | Common Stock | I | 8,9700 | −5 121 | −46 | 490 711 | ||||
| 2014-12-17 | 2014-12-15 | 4 | HENOS MICHAEL A By funds | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −38 493 | 0 | |||||
| 2014-12-17 | 2014-12-15 | 4 | HENOS MICHAEL A By funds | GLYC | Warrant to Purchase Common Stock (right to buy) | I | 0,33 | −5 133 | 0 | |||||
| 2014-12-17 | 2014-12-15 | 4 | HENOS MICHAEL A By funds | GLYC | Common Stock | I | 8,9800 | −1 604 | −14 | 495 832 | ||||
| 2014-12-17 | 2014-12-15 | 4 | HENOS MICHAEL A By funds | GLYC | Common Stock | I | 0,3300 | 43 628 | 14 | 497 436 | ||||
| 2014-07-10 | 3 | Goldberg Mark Alan | GLYC | Common Stock | D | 2 200 | ||||||||
| 2014-07-10 | 3 | Goldberg Mark Alan | GLYC | Common Stock | D | 2 200 | ||||||||
| 2014-07-10 | 2014-07-08 | 4 | Goldberg Mark Alan | GLYC | Stock Option (right to buy) | D | 8,86 | 15 401 | 15 401 | |||||
| 2014-06-20 | 2014-06-18 | 4 | King Rachel K. | GLYC | Employee Stock Option (right to buy) | D | 1,12 | −100 000 | 347 580 | |||||
| 2014-06-20 | 2014-06-18 | 4 | King Rachel K. | GLYC | Common Stock | D | 1,1200 | 100 000 | 112 | 108 706 | ||||
| 2014-06-13 | 2014-06-13 | 4 | HENOS MICHAEL A | GLYC | Common Stock | D | 6,2100 | 5 000 | 31 | 12 562 | ||||
| 2014-06-13 | 2014-06-12 | 4 | HENOS MICHAEL A | GLYC | Common Stock | D | 6,5400 | 6 000 | 39 | 7 562 | ||||
| 2014-04-03 | 2014-04-03 | 4 | HENOS MICHAEL A | GLYC | Stock Option (right to buy) | D | 1,12 | −1 562 | 0 | |||||
| 2014-04-03 | 2014-04-03 | 4 | HENOS MICHAEL A | GLYC | Common Stock | D | 1,1200 | 1 562 | 2 | 1 562 | ||||
| 2014-04-01 | 3 | PEARSON TIMOTHY R | GLYC | No securities beneficially owned | D | 0 | ||||||||
| 2014-04-01 | 2014-03-31 | 4 | PEARSON TIMOTHY R | GLYC | Stock Option (right to buy) | D | 16,33 | 15 401 | 15 401 | |||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Series A-1 Preferred Stock | D | −11 250 850 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 8,0000 | 487 500 | 3 900 | 4 481 758 | ||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 10 L P | GLYC | Common Stock | D | 3 407 283 | 3 994 258 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 4 | GLYC | Series A-1 Preferred Stock | I | −11 824 058 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 3 | GLYC | Series A-1 Preferred Stock | I | −11 250 850 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 4 | GLYC | Common Stock | I | 8,0000 | 512 500 | 4 100 | 4 093 377 | ||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 4 | GLYC | Common Stock | I | 3 580 877 | 3 580 877 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 3 | GLYC | Common Stock | I | 8,0000 | 487 500 | 3 900 | 4 481 758 | ||||
| 2014-01-15 | 2014-01-15 | 4 | BARRETT M JAMES See Note 3 | GLYC | Common Stock | I | 3 407 283 | 3 994 258 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 4 | GLYC | Series A-1 Preferred Stock | I | −11 824 058 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 3 | GLYC | Series A-1 Preferred Stock | I | −11 250 850 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 4 | GLYC | Common Stock | I | 8,0000 | 512 500 | 4 100 | 4 093 377 | ||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 4 | GLYC | Common Stock | I | 3 580 877 | 3 580 877 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 3 | GLYC | Common Stock | I | 8,0000 | 487 500 | 3 900 | 4 481 758 | ||||
| 2014-01-15 | 2014-01-15 | 4 | BARRIS PETER J See Note 3 | GLYC | Common Stock | I | 3 407 283 | 3 994 258 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 4 | GLYC | Series A-1 Preferred Stock | I | −11 824 058 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Series A-1 Preferred Stock | I | −11 250 850 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 4 | GLYC | Common Stock | I | 8,0000 | 512 500 | 4 100 | 4 093 377 | ||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 4 | GLYC | Common Stock | I | 3 580 877 | 3 580 877 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 8,0000 | 487 500 | 3 900 | 4 481 758 | ||||
| 2014-01-15 | 2014-01-15 | 4 | SANDELL SCOTT D See Note 3 | GLYC | Common Stock | I | 3 407 283 | 3 994 258 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | HENOS MICHAEL A By Funds | GLYC | Series A-1 Preferred Stock | I | −1 114 690 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | HENOS MICHAEL A By Spouse | GLYC | Series A-1 Preferred Stock | I | −39 413 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | HENOS MICHAEL A By Funds | GLYC | Common Stock | I | 337 579 | 453 808 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | HENOS MICHAEL A By Spouse | GLYC | Common Stock | I | 11 936 | 22 668 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 13 LP | GLYC | Series A-1 Preferred Stock | D | −11 824 058 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 13 LP | GLYC | Common Stock | D | 8,0000 | 512 500 | 4 100 | 4 093 377 | ||||
| 2014-01-15 | 2014-01-15 | 4 | NEW ENTERPRISE ASSOCIATES 13 LP | GLYC | Common Stock | D | 3 580 877 | 3 580 877 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | Magnani John L. | GLYC | Series A-1 Preferred Stock | D | −32 918 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | Magnani John L. | GLYC | Common Stock | D | −9 969 | 90 374 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | Gust William M. By Anthem Capital | GLYC | Series A-1 Preferred Stock | I | −1 121 646 | 0 | ||||||
| 2014-01-15 | 2014-01-15 | 4 | Gust William M. By Anthem Capital | GLYC | Common Stock | I | 339 686 | 409 947 | ||||||
| 2014-01-13 | 2014-01-09 | 4 | BARRETT M JAMES | GLYC | Stock Option (right to buy) | D | 8,00 | 15 401 | 15 401 | |||||
| 2014-01-13 | 2014-01-09 | 4 | HENOS MICHAEL A | GLYC | Stock Option (right to buy) | D | 8,00 | 15 401 | 15 401 | |||||
| 2014-01-13 | 2014-01-09 | 4 | TOP FRANKLIN H JR | GLYC | Stock Option (right to buy) | D | 8,00 | 15 401 | 15 401 | |||||
| 2014-01-13 | 2014-01-09 | 4 | Hahn Brian M. | GLYC | Stock Option (right to buy) | D | 8,00 | 37 564 | 37 564 | |||||
| 2014-01-13 | 2014-01-09 | 4 | King Rachel K. | GLYC | Stock Option (right to buy) | D | 8,00 | 375 639 | 375 639 | |||||
| 2014-01-13 | 2014-01-09 | 4 | Gust William M. | GLYC | Stock Option (right to buy) | D | 8,00 | 15 401 | 15 401 | |||||
| 2014-01-13 | 2014-01-09 | 4 | Magnani John L. | GLYC | Stock Option (right to buy) | D | 8,00 | 169 038 | 169 038 | |||||
| 2014-01-13 | 2014-01-09 | 4 | Thackray Helen M. | GLYC | Stock Option (right to buy) | D | 8,00 | 112 692 | 112 692 | |||||
| 2014-01-13 | 2014-01-09 | 4 | Baldwin John J. | GLYC | Stock Option (right to buy) | D | 8,00 | 15 401 | 15 401 | |||||
| 2014-01-09 | 3 | NEA PARTNERS 10 L P | GLYC | Common Stock | D | 586 975 | ||||||||
| 2014-01-09 | 3 | BARRETT M JAMES See Note 1 | GLYC | Common Stock | I | 586 975 | ||||||||
| 2014-01-09 | 3 | SANDELL SCOTT D See Note 1 | GLYC | Common Stock | I | 586 975 | ||||||||
| 2014-01-09 | 3 | BARRIS PETER J See Note 1 | GLYC | Common Stock | I | 586 975 | ||||||||
| 2014-01-09 | 3 | HENOS MICHAEL A By Spouse | GLYC | Common Stock | I | 10 732 | ||||||||
| 2014-01-09 | 3 | HENOS MICHAEL A By Funds | GLYC | Common Stock | I | 116 229 | ||||||||
| 2014-01-09 | 3 | TOP FRANKLIN H JR | GLYC | Common Stock | D | 605 | ||||||||
| 2014-01-09 | 3 | Hahn Brian M. | GLYC | Common Stock | D | 9 085 | ||||||||
| 2014-01-09 | 3 | King Rachel K. By Trusts | GLYC | Common Stock | I | 157 355 | ||||||||
| 2014-01-09 | 3 | King Rachel K. | GLYC | Common Stock | D | 8 706 | ||||||||
| 2014-01-09 | 3 | King Rachel K. By Spouse | GLYC | Common Stock | I | 1 741 | ||||||||
| 2014-01-09 | 3 | Magnani John L. | GLYC | Common Stock | D | 80 405 | ||||||||
| 2014-01-09 | 3 | Magnani John L. By GlycoTech Corporation | GLYC | Common Stock | I | 4 845 | ||||||||
| 2014-01-09 | 3 | Gust William M. By Anthem Capital | GLYC | Common Stock | I | 70 261 | ||||||||
| 2014-01-09 | 3 | Thackray Helen M. | GLYC | Common Stock | D | 184 615 | ||||||||
| 2014-01-09 | 3 | Baldwin John J. | GLYC | Common Stock | D | 605 | ||||||||
| 2013-11-07 | 3 | Sanofi Via wholly-owned subsidiary, Genzyme Corp. | GLYC | Preferred Stock | I | 1 193 625 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
